| 3.43 0.41 (13.58%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.19 |
1-year : | 4.89 |
| Resists | First : | 3.58 |
Second : | 4.19 |
| Pivot price | 2.88 |
|||
| Supports | First : | 2.56 |
Second : | 1.92 |
| MAs | MA(5) : | 3.14 |
MA(20) : | 2.7 |
| MA(100) : | 3.06  |
MA(250) : | 10 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 85.4 |
D(3) : | 87.2 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 47.59 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INDP ] has closed above the upper band by 3.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 50% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.59 - 3.61 | 3.61 - 3.63 |
| Low: | 2.97 - 2.99 | 2.99 - 3.01 |
| Close: | 3.4 - 3.43 | 3.43 - 3.46 |
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Thu, 08 Jan 2026
Indaptus Therapeutics Appoints David Natan to Board - The Globe and Mail
Fri, 02 Jan 2026
Indaptus Therapeutics announces upcoming board leadership transition - TipRanks
Fri, 02 Jan 2026
Three Indaptus Therapeutics board members signal planned resignations - Investing.com
Mon, 29 Dec 2025
Indaptus Therapeutics stock falls after $6 million securities deal - Investing.com
Thu, 25 Dec 2025
What Does the Market Think About Indaptus Therapeutics Inc? - Sahm
Wed, 24 Dec 2025
Is It Too Late to Buy INDP Stock? - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 31.6 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -29.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -131.4 % |
| Return on Equity (ttm) | -318 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|